Stateman -- With its cash dwindling, Introgen Therapeutics Inc. said Tuesday that it has hired an adviser to pursue strategic options, including a possible sale. The news came as the Austin-based biotechnology company reported a third-quarter net loss of $6 million, or 14 cents a share, on revenue of $331,000. That compares with a net loss of $7.5 million, or 17 cents a share, on revenue of $139,000 during the same quarter a year ago.
